Professor David Gonzalez de Castro was appointed as Professor of Genomic Medicine in May 2016.  His research is centred around molecular biomarker analysis and developing genomic stratification tools for precision medicine with particular focus on developing biomarker strategies for immunotherapeutics and using circulating biomarkers to better classify and monitor disease.  He is involved in several translational research projects identifying diagnostic, predictive and prognostics molecular biomarkers in haematological and solid tumours.  

Professor Gonzalez de Castro has been one of the principal investigators on the CRUK stratified medicines programme since 2011, working in close collaboration with clinicians and pharmaceutical and biotechnology industry.  For the last 12 years he has been the Head of the Molecular Diagnostics department at the Royal Marsden and the Institute of Cancer Research in London, where he has been leading the implementation of genomic medicine-driven clinical trials in multiple cancer types, including leukaemias, soft-tissue sarcomas, gastric, colon, lung, skin, prostate, breast and other tumours. He joins CCRCB and the NI-MPL as a Consultant Clinical Scientist, where he aims to further develop genomic stratification protocols to improve patients’ outcomes.